

## **VIAMET PHARMACEUTICALS EXPANDS PHASE 2 CLINICAL PROGRAM WITH NOVEL ANTIFUNGAL AGENT VT-1161**

*Company announces the initiation of a second Phase 2 study with the novel antifungal agent VT-1161.*

September 24, 2013, Research Triangle Park, North Carolina – [Viamet Pharmaceuticals, Inc.](#) announced today the expansion of the phase 2 clinical program for the novel antifungal agent VT-1161. The initial phase 2 study previously announced is designed to evaluate the safety and efficacy of VT-1161 in the oral treatment of acute vulvovaginal candidiasis (VVC). A second phase 2 clinical study has been initiated to evaluate the safety and efficacy of VT-1161 in the oral treatment of moderate to severe interdigital tinea pedis, commonly called athlete's foot. Both studies are being conducted at leading clinical centers in the United States. VT-1161 has been shown in preclinical studies to potently inhibit, in a safe and selective manner, a wide range of fungal pathogens causing human disease. In previous phase 1 clinical studies, VT-1161 demonstrated good safety, tolerability and pharmacokinetics.

“VT-1161 is a novel, potent and selective compound that is active against a wide range of fungal pathogens including dermatophytes and yeasts”, said Robert Schotzinger, M.D., Ph.D., President and Chief Executive Officer of Viamet. “Our ongoing clinical trials in tinea pedis and acute VVC will provide valuable insight into the ability of VT-1161 to treat onychomycosis and recurrent VVC, two areas of significant unmet medical need.”

“Onychomycosis, also known as fungal infection of the nail, is one of the most common infections in humans. Current oral therapies for the treatment of onychomycosis are only marginally effective and have significant safety liabilities such as liver toxicity”, noted Dr. Schotzinger. “Topical treatments for onychomycosis, while safer, have limited efficacy. In addition, all current therapies for onychomycosis suffer from high recurrence rates of infection. There is a tremendous need for newer, oral therapies with improved efficacy and safety profiles and reduced rates of recurrence.”

VT-1161 is one of several novel, small molecule compounds currently under development at Viamet for the treatment of fungal infections. VT-1129 is a potent and selective, oral, preclinical development candidate for the treatment of cryptococcal meningitis and other serious invasive fungal diseases. Several additional injectable and orally-administered molecules are in early-stage development for the treatment of invasive yeast and mold infections commonly encountered in the hospital. All of the Viamet antifungal candidates have been discovered and developed utilizing the company's Metallophile<sup>®</sup> Technology platform.

### **About the Viamet Group of Companies ([www.viamet.com](http://www.viamet.com))**

Viamet discovers and develops best-in-class inhibitors of key metalloenzymes via a proprietary platform, called the Metallophile<sup>®</sup> Technology. The Metallophile Technology is based on the Company's world-class expertise in bioinorganic chemistry and an extensive understanding of metalloenzyme structure and function. The Metallophile Technology has enabled Viamet to rapidly build a portfolio of proprietary clinical compounds and drug candidates that address significant unmet medical needs and represent significant commercial potential. The most advanced of these molecules are VT-464, an orally-active small molecule inhibitor of the enzyme CYP17 lyase, which is in phase 1/2 clinical development for the treatment of castration-resistant prostate cancer, and VT-1161, an orally-active small molecule inhibitor of the fungal CYP51 enzyme, which recently completed phase 1 clinical testing with target indications of onychomycosis and recurrent vulvovaginal candidiasis.

#### *Contact:*

Rich Katz, M.D., Chief Business and Financial Officer  
Viamet Pharmaceuticals, Inc.  
4505 Emperor Boulevard, Suite 300  
Durham, North Carolina, USA 27703  
Telephone: +919.467.8539 ext. 316

This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet's business and VT-1161, including that clinical trials may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success.

The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-1, Inc., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies is based in the Research Triangle Park region of North Carolina, USA.